4 Medical Device Stocks to Buy for Healthy Returns in 2026
View original at finance.yahoo.com4 Medical Device Stocks to Buy for Healthy Returns in 2026 2025 brought ups and downs for the MedTech industry. Under President Trump’s second term, shifting trade policies, including new and heightened threats of tariffs, sanctions and other restrictions, created significant uncertainties…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Intuitive Surgical carries a Zacks Rank #1 (Strong Buy)
80% confidenceThe digital twins market is forecasted to expand at a 16.6% CAGR between 2025 and 2032
80% confidenceIDEXX's 2026 revenues and EPS are likely to increase 8.9% and 11.6%, respectively
80% confidenceBoston Scientific carries a Zacks Rank #2 (Buy)
80% confidenceInsulet holds a Zacks Rank #2 (Buy)
80% confidenceM&A activity shifted toward fewer but larger deals, with average transaction size rising 11% from 2024
80% confidenceThrough September 2025, the FDA's list of AI-enabled device authorizations included more than 250 devices, with Radiology taking the lead
80% confidenceFor 2026, Insulet revenues and EPS are expected to grow 19.8% and 26.3%, respectively
80% confidenceAI-assisted robotic surgeries demonstrated a 25% reduction in operative time and a 30% decrease in intraoperative complications compared to manual methods
80% confidenceFor 2026, Intuitive Surgical revenues are expected to grow 14.3%, whereas earnings per share are expected to rise 11.2%
80% confidenceFor 2026, Boston Scientific revenues and EPS are expected to jump 11.1% and 13.6%, respectively
80% confidenceThe global medical device market is expected to expand at a CAGR of 5.94% from 2026 to 2035
80% confidenceIDEXX Laboratories carries a Zacks Rank #2 (Buy)
80% confidenceMore Omnipod 5 rollouts are planned in 2026, while Libre 3 integration in the United States remains on track for the first half of 2026
80% confidenceThe MedTech industry generated $584 billion in revenues in 2025, marking its seventh consecutive year of top-line growth
80% confidenceIDEXX plans to expand the Cancer Dx franchise in 2026 by adding mast cell tumor and introducing it in international markets
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · ai device authorizations | 250 devices |